Introduction {#dom12576-sec-0001}
============

Recently, we reported that inhibition of N‐Methyl‐D‐Aspartate receptors (NMDARs) in mouse and human pancreatic islets enhanced glucose‐stimulated insulin secretion and islet cell survival [1](#dom12576-bib-0001){ref-type="ref"}. Furthermore, we observed that, *in vivo*, the NMDAR antagonist and over‐the‐counter antitussive agent dextromethorphan (DXM) enhanced glucose tolerance in mice, and that *in vitro* dextrorphan, the main metabolite of the pro‐drug DXM, amplified the stimulatory effect of exendin‐4, a peptide agonist of the glucagon‐like peptide‐1 receptor, on glucose‐stimulated insulin secretion [1](#dom12576-bib-0001){ref-type="ref"}. Moreover, a randomized clinical trial showed that DXM selectively increased postprandial serum insulin concentrations and lowered blood glucose (BG) excursions in individuals with type 2 diabetes mellitus (T2DM) [1](#dom12576-bib-0001){ref-type="ref"}.

Like NMDAR antagonists, dipeptidyl peptidase‐4 (DPP‐4) inhibitors, such as sitagliptin, enhance postprandial serum insulin concentrations and improve BG control, but through another mechanism of action [1](#dom12576-bib-0001){ref-type="ref"}, [2](#dom12576-bib-0002){ref-type="ref"}, [3](#dom12576-bib-0003){ref-type="ref"}, [4](#dom12576-bib-0004){ref-type="ref"}, [5](#dom12576-bib-0005){ref-type="ref"}. The primary objective of the present study was to investigate whether the combination of a low dose of DXM and sitagliptin exerts additive BG‐lowering effects after an oral glucose load compared with sitagliptin alone and DXM alone.

Methods {#dom12576-sec-0002}
=======

Eligible subjects were men aged 45--70 years, with a diagnosis of T2DM according to American Diabetes Association criteria at least 4 months before screening, who were on a stable regimen of metformin monotherapy for at least 3 months, and who had a medical history without major pathology, a body mass index of 25--35 kg/m^2^ and a glycated haemoglobin concentration ≥6.5 and ≤8.0% (Table S1). The study was conducted at Profil, Neuss, Germany. The Ethics committee of the Ärztekammer Nordrhein, Düsseldorf, Germany, approved the trial protocol. The trial was conducted in accordance with the Declaration of Helsinki (2008) and International Conference on Harmonisation Good Clinical Practice (1996), and written informed consent was obtained from all patients. The trial was registered at [ClinicalTrials.gov](http://ClinicalTrials.gov) (NCT01936025).

Study participants received either 30, 60 or 90 mg DXM, 100 mg sitagliptin, 30, 60 or 90 mg DXM plus 100 mg sitagliptin, or placebo in the morning after an overnight fast on a total of eight treatment days. One hour after study drug administration an oral glucose tolerance test (OGTT) with 75 g glucose was started. The primary objectives of the present clinical trial were to (i) find the lowest dose of DXM that, compared with placebo, exerted a BG‐lowering effect related to the OGTT, and (ii) investigate whether the combination of DXM and sitagliptin had additive BG‐lowering effects compared with each drug alone (to convert mg/dl to mmol/l, multiply by 0.0555). The primary pharmacodynamic variable was the area under the curve (AUC) of BG concentrations 0--2 h after starting the OGTT: AUC~glucose\ 1--3\ h~. Further pharmacodynamic variables included AUC~glucose\ 0--1\ h~, AUC~glucose\ 3--5\ h~, maximum glucose concentration, AUC~insulin\ 0--1\ h~, AUC~insulin\ 1--1.5\ h~, AUC~insulin\ 1--3\ h~, AUC~insulin\ 3--5\ h~, and maximum insulin concentration. Insulin values after starting the OGTT were adjusted for baseline levels to correct for endogenous insulin secretion, meaning that predose concentrations were subtracted from subsequent measurements before calculation.

All statistical analyses were performed using [sas]{.smallcaps} software. The primary endpoint AUC~glucose\ 1--3\ h~ was analysed using a mixed model, with treatment as fixed factor and subject as random factor. Normally or log‐normally distributed secondary endpoints were analysed using the same approach as specified for the primary pharmacodynamic analysis using untransformed or log‐transformed endpoints. Time variables and non‐normal or non‐log‐normal distributed endpoints were analysed by non‐parametric technique using Wilcoxon\'s signed rank test and corresponding Hodges and Lehmann 95% confidence intervals (CIs).

Results {#dom12576-sec-0003}
=======

A total of 20 men with T2DM were enrolled and completed the clinical trial (Table S1; Figure S1). To a small, but not significant extent, all doses of DXM alone were found to numerically reduce maximum BG concentrations and AUC~glucose\ 1--3\ h~, whereas only 60 mg DXM numerically reduced AUC~glucose\ 3--5\ h~ compared with placebo (Table [1](#dom12576-tbl-0001){ref-type="table-wrap"}). When DXM was used as add‐on to sitagliptin, all doses of DXM plus sitagliptin showed numerically lower values compared with sitagliptin alone for maximum BG concentrations, AUC~glucose\ 1--3\ h~, and AUC~glucose\ 3--5\ h~ (Table [1](#dom12576-tbl-0001){ref-type="table-wrap"}); the latter variable showed the least reduction with the lowest dose of DXM (30 mg) plus sitagliptin (Table [1](#dom12576-tbl-0001){ref-type="table-wrap"}). Notably, 60 mg DXM plus sitagliptin was observed to significantly lower maximum BG concentrations compared with sitagliptin alone (Figure [1](#dom12576-fig-0001){ref-type="fig"}A, B; Table [1](#dom12576-tbl-0001){ref-type="table-wrap"}). For 30, 60 and 90 mg DXM added to sitagliptin, BG reductions within 4 h after starting the OGTT (i.e. % reductions in AUC~glucose\ 1--5\ h~) of 8.9, 10.5 and 10.7% were observed, respectively, as compared with only 6.5% with sitagliptin alone (Table S2). By contrast, virtually no reductions in pre‐OGTT fasting BG concentrations were observed (Table S3).

###### 

Glucose, insulin and glucagon concentrations after starting the oral glucose tolerance test.

                         Maximum glucose, mg/dl   Maximum insulin, mU/l   Maximum glucagon, pmol/l   AUC~insulin\ 1--1.5\ h~, mU/l/h   AUC~glucose\ 1--3\ h~, mg/dl/h   AUC~insulin\ 1--3\ h~, mU/l/h   AUC~glucagon\ 1--3\ h~, pmol/l/h   AUC~glucose\ 3--5\ h~, mg/dl/h   AUC~insulin\ 3--5\ h~, mU/l/h
  ---------------------- ------------------------ ----------------------- -------------------------- --------------------------------- -------------------------------- ------------------------------- ---------------------------------- -------------------------------- -------------------------------
  Placebo                271.8 ± 49.3             56.2 ± 35.9             56.6 ± 11.4                3.9 ± 3.0                         444.7 ± 69.3                     63.9 ± 38.6                     102.3 ± 19.6                       388.4 ± 99.4                     49.6 ± 36.5
  Sitagliptin            254.4 ± 49.7\*           71.8 ± 43.5\*           55.7 ± 11.7                5.8 ± 2.5                         412.4 ± 74.3\*                   77.1 ± 39.4\*                   100.7 ± 19.6                       366.5 ± 101.5                    74.1 ± 42.2\*
  DXM 30                 264.5 ± 43.6             57.6 ± 30.6‡            Not analysed               5.6 ± 4.2                         430.2 ± 64.2                     68.7 ± 39.3                     Not analysed                       390.3 ± 89.7‡                    56.4 ± 39.0
  DXM 30 + sitagliptin   243.1 ± 45.0\*\*†        71.9 ± 42.5\*†          8.4 ± 6.4\*\*†‡            393.2 ± 77.9\*\*†                 81.4 ± 47.8\*†                   365.6 ± 91.9†                   73.2 ± 40.8\*†                                                      
  DXM 60                 262.4 ± 45.0             69.1 ± 46.8             56.1 ± 10.1                3.9 ± 2.2                         425.2 ± 78.0                     74.2 ± 46.0                     100.1 ± 15.2                       374.6 ± 104.6                    63.5 ± 49.8
  DXM 60 + sitagliptin   240.1 ± 47.0\*\*†‡       78.6 ± 52.6\*\*†        55.7 ± 12.8                8.1 ± 6.1\*\*††‡                  393.3 ± 73.1\*\*†                89.0 ± 53.5\*\*†                101.2 ± 20.7                       352.8 ± 100.4\*                  70.8 ± 42.7\*
  DXM 90                 270.2 ± 50.4‡            60.1 ± 42.3‡            Not analysed               4.4 ± 5.2                         433.4 ± 76.2                     67.0 ± 49.3‡                    Not analysed                       390.2 ± 103.0                    53.4 ± 40.2‡
  DXM 90 + sitagliptin   243.4 ± 52.6\*\*††       87.0 ± 57.5\*\*††‡      7.6 ± 4.7\*\*†             391.0 ± 92.2\*\*††                88.3 ± 51.2\*\*††                353.1 ± 103.7\*†                74.1 ± 47.9\*†                                                      

Data are presented as means ± standard deviation. Maximum insulin concentrations and AUC insulin data were baseline adjusted. Statistical analyses for BG concentrations and serum insulin concentrations were performed using a linear mixed model, with treatment as fixed factors and subject as a random factor using untransformed and, when needed, log‐transformed endpoints. Statistical analyses of plasma glucagon concentrations were performed using the Wilcoxon signed rank test based on a two‐sided α of 5% and calculation of Hodges and Lehman estimates and corresponding non‐parametric confidence intervals. AUC, area under the curve; DXM, dextromethorphan; OGTT, oral glucose tolerance test.

\*p \< 0.05 and \*\*p \< 0.001 sitagliptin alone, DXM alone and sitagliptin + DXM versus placebo; †p \< 0.05 and ††p \< 0.001 sitagliptin + DXM versus DXM alone at same dose; ‡p \< 0.05 DXM alone and sitagliptin + DXM versus sitagliptin alone.

![Oral glucose tolerance test and serum insulin concentrations in individuals with type 2 diabetes (T2DM). Blood glucose concentrations in 20 men with T2DM before and during an oral glucose tolerance test (OGTT) shown for (A) placebo versus 100 mg sitagliptin and (B) placebo versus 100 mg sitagliptin plus 60 mg dextromethorphan (DXM). (C) Serum insulin concentrations during the first 30 min after starting the OGTT after administration of placebo, 100 mg sitaglipin and 100 mg sitagliptin plus 60 mg DXM. Significance (\*p \< 0.05) was determined by a linear mixed model, with treatment as a fixed factor and subject as a random factor using untransformed endpoints. All values are means ± standard deviation.](DOM-18-100-g001){#dom12576-fig-0001}

With regard to postprandial serum insulin concentrations, all doses of DXM alone compared with placebo were found to numerically increase maximum insulin concentrations to a small, but not significant extent (Table [1](#dom12576-tbl-0001){ref-type="table-wrap"}). Sitagliptin alone and all sitagliptin plus DXM combinations led to significant increases in maximum insulin concentrations, but the combination of 90 mg DXM plus sitagliptin resulted in significantly higher increases in the maximum insulin concentrations versus sitagliptin alone (Table [1](#dom12576-tbl-0001){ref-type="table-wrap"}). All doses of DXM plus sitagliptin numerically increased the baseline‐adjusted AUC~insulin\ 1--1.5\ h~; that is, the amount of serum insulin during the first 30 min of the OGTT, compared with sitagliptin alone (Table [1](#dom12576-tbl-0001){ref-type="table-wrap"}). This increase was significant for the combination of 30 mg DXM plus sitagliptin and 60 mg DXM plus sitagliptin (95% CI 0.46, 4.73; p = 0.017, and 95% CI 0.11, 4.38; p = 0.039, respectively) when compared with sitagliptin alone (Figure [1](#dom12576-fig-0001){ref-type="fig"}C, Table [1](#dom12576-tbl-0001){ref-type="table-wrap"}). The combination of 30 mg DXM plus sitagliptin and 60 mg DXM plus sitagliptin compared with placebo increased the baseline‐adjusted AUC~insulin\ 1--1.5\ h~ by ∼110% versus an increase of only ∼50% for sitagliptin alone compared with placebo (Figure [1](#dom12576-fig-0001){ref-type="fig"}C, Table [1](#dom12576-tbl-0001){ref-type="table-wrap"}). Notably, within the setting of the present trial, 100 mg sitagliptin alone failed to significantly increase the baseline‐adjusted AUC~insulin\ 1--1.5\ h~ (95% CI −0.22, 4.05; p = 0.078). Sitagliptin versus placebo, and sitagliptin plus all DXM combinations versus placebo, however, led to significant increases in the baseline‐adjusted AUC~insulin\ 1--3\ h~ after starting the OGTT, with higher significance noted for the combinations of sitagliptin plus DXM (Table [1](#dom12576-tbl-0001){ref-type="table-wrap"}). By contrast, the addition of DXM to sitagliptin did not increase the baseline‐adjusted AUC~insulin\ 3--5\ h~ compared with sitagliptin alone (Table [1](#dom12576-tbl-0001){ref-type="table-wrap"}). All DXM dosages plus sitagliptin versus placebo were observed to result in small increases in fasting serum insulin concentrations before starting the OGTT, whereas no significant changes in fasting BG concentrations were observed (Table S3). As compared with placebo, plasma glucagon concentrations remained virtually unchanged after administration of the study medications, both before and after starting the OGTT (Tables [1](#dom12576-tbl-0001){ref-type="table-wrap"} and S3).

All dosages of study medication were well tolerated, and few adverse events were observed after administration of DXM alone or none after the combination of 30 mg DXM plus sitagliptin. With regard to the combinations of 60 mg or 90 mg DXM plus sitagliptin, only one mild adverse event (fatigue) was observed each.

Discussion {#dom12576-sec-0004}
==========

In this single‐dose, double‐blinded clinical trial, we provided a proof of concept that addition of low doses of DXM, including 30 mg (a dose used as over‐the‐counter medication for cough suppression), to sitagliptin substantially increased early postprandial serum insulin concentrations and reduced BG excursions during an OGTT without inducing hypoglycaemia. More specifically, the postprandial serum insulin concentrations during the first 30 min of the OGTT were strongly increased by the addition of DXM to sitagliptin, whereas postprandial serum insulin concentrations during the last 2 h of the OGTT were not increased at all. This points to the possibility that the combination of DXM and sitagliptin preferentially restores the early phase of insulin release in individuals with T2DM, with BG‐lowering effects lasting throughout the entire OGTT; however, the question of whether a normal β‐cell physiology could be restored in individuals with T2DM by this combination requires further clinical tests, more directly addressing insulin secretion in these patients [6](#dom12576-bib-0006){ref-type="ref"}. The findings of the present trial highlight an additive action of DXM and sitagliptin (Figure [1](#dom12576-fig-0001){ref-type="fig"}), most likely because they target pancreatic β‐cell NMDARs and incretin receptors, respectively, which enhance glucose‐stimulated insulin release from human pancreatic islets via different glutamate‐dependent molecular mechanisms [1](#dom12576-bib-0001){ref-type="ref"}, [2](#dom12576-bib-0002){ref-type="ref"}, [7](#dom12576-bib-0007){ref-type="ref"}, [8](#dom12576-bib-0008){ref-type="ref"}.

The present study shows for the first time that addition of DXM increases the BG‐lowering effects of the DPP‐4 inhibitor sitagliptin, which is a popular oral antidiabetic medication, but only reduces BG levels in patients with T2DM to a moderate extent compared with incretin‐based peptides requiring regular injections [9](#dom12576-bib-0009){ref-type="ref"}. Consistently, sitagliptin only lowered AUC~glucose\ 1--3\ h~ by ∼7% in the present study, whereas the combinations of a low dose of DXM with sitagliptin reduced this primary endpoint by ∼12%. Our findings now warrant further and long‐term clinical trials on the combined action of DXM and incretin‐based diabetes therapies so as to draw conclusions on the clinical relevance of this combination, in particular concerning the preservation of β‐cell function and mass that has been described for DXM in preclinical studies [1](#dom12576-bib-0001){ref-type="ref"}, [10](#dom12576-bib-0010){ref-type="ref"}.
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**Figure S1.** Consort flow diagram.
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**Table S1.** Baseline demographic and clinical characteristics of the study sample.
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**Table S2.** Glucose, insulin and glucagon concentrations during the entire oral glucose tolerance test.
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**Table S3.** Glucose, insulin and glucagon concentrations after study drug administration, but [before]{.ul} starting the OGTT. Data are presented as means ± SD. Statistical analyses for BG concentrations and serum insulin concentrations were performed using a linear mixed model with treatment as fixed factors and subject as a random factor using untransformed and, when needed, log‐transformed endpoints. Statistical analyses of plasma glucagon concentrations were performed using the Wilcoxon Signed Rank test based on a two‐sided alpha of 5% and calculation of Hodges and Lehman estimates and corresponding nonparametric confidence intervals. Data are presented as means ± SD. \*p \< 0.05 versus placebo; †p \< 0.05 versus DXM alone at same dose; ‡p \< 0.05 versus Sita alone.
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